Scarica l'app Stockscreener
47.71
1.47%
0.69
Dopo l'orario di chiusura:
47.71
Precedente Chiudi:
$47.02
Aprire:
$46.48
Volume 24 ore:
581.93K
Relative Volume:
1.24
Capitalizzazione di mercato:
$2.71B
Reddito:
-
Utile/perdita netta:
$-118.49M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-110.57M
1 W Prestazione:
+7.21%
1M Prestazione:
+5.93%
6M Prestazione:
+25.39%
1 anno Prestazione:
+92.46%
Intervallo 1D:
$45.51
$48.42
Intervallo di 1 settimana:
$43.69
$48.85
Portata 52W:
$24.88
$72.29
Apogee Therapeutics Inc Stock (APGE) Company Profile
Nome
Apogee Therapeutics Inc
Settore
Industria
Telefono
650-394-5230
Indirizzo
221 CRESCENT ST., WALTHAM
Confronta APGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
47.71 | 2.71B | 0 | -118.49M | -110.57M | -2.4041 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-25 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-10 | Iniziato | BofA Securities | Buy |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | Guggenheim | Buy |
| 2023-08-08 | Iniziato | Jefferies | Buy |
| 2023-08-08 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
| 2023-08-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Apogee Therapeutics Inc Borsa (APGE) Ultime notizie
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 3.2%Here's Why - MarketBeat
Trend Tracker for (APGE) - Stock Traders Daily
Franklin Resources Inc. Has $48.05 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Trading Up 6.1% After Insider Buying Activity - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Price Target at $83.88 - Defense World
Apogee Therapeutics (NASDAQ:APGE) Trading 6.1% Higher Following Insider Buying Activity - MarketBeat
State Street Corp Cuts Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up Following Insider Buying Activity - Defense World
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up After Insider Buying Activity - MarketBeat
Insider Buying: Mark Mckenna Acquires 20,000 Shares of Apogee Th - GuruFocus.com
Apogee Therapeutics, Inc. (NASDAQ:APGE) Director Mark C. Mckenna Acquires 20,000 Shares of Stock - MarketBeat
Apogee Therapeutics : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.com
Apogee Therapeutics director Mark McKenna acquires $990,775 in stock - Investing.com
Apogee Therapeutics director Mark McKenna acquires $990,775 in stock By Investing.com - Investing.com South Africa
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.89 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Sees Large Growth in Short Interest - MarketBeat
Barclays PLC Grows Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,540 Shares - MarketBeat
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $83.88 - MarketBeat
Apogee Therapeutics' chief medical officer sells $221,362 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics' chief medical officer sells $221,362 in stock - Investing.com
Financial Survey: Apogee Therapeutics (NASDAQ:APGE) versus DBV Technologies (NASDAQ:DBVT) - Defense World
Guggenheim maintains buy on Apogee stock amid trial failures - Investing.com
Apogee Therapeutics, Inc. Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions - Marketscreener.com
Apogee Therapeutics Advances Clinical Trials for APG333 - TipRanks
Apogee Therapeutics Announces First Participants Dosed in - GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its - The Bakersfield Californian
Apogee Therapeutics Launches Phase 1 Trial for Novel Asthma Treatment, Marking 4th Clinical Program - StockTitan
Wellington Management Group LLP Buys 1,267,451 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Position Boosted by Charles Schwab Investment Management Inc. - MarketBeat
Carl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $698,700.00 in Stock - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Janus Henderson Group PLC - MarketBeat
Apogee Therapeutics CEO Michael Henderson sells shares worth $698,653 By Investing.com - Investing.com Nigeria
Apogee Therapeutics CEO Michael Henderson sells shares worth $698,653 - Investing.com
Apogee Therapeutics' chief medical officer sells shares worth $307,056 By Investing.com - Investing.com UK
Point72 Asset Management L.P. Increases Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Guggenheim Reaffirms Buy Rating for Apogee Therapeutics (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by HighVista Strategies LLC - MarketBeat
Apogee Therapeutics Advances in I&I Disease Treatments - Yahoo Finance
Apogee Therapeutics Highlights Progress and Potential in Biologic Programs at R&D Day - Defense World
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $90.00 at Wedbush - Defense World
Apogee Therapeutics Highlights Progress and Best-in-Class - GlobeNewswire
Apogee Therapeutics Highlights Progress and Best-In-Class Potential of Novel Biologic Programs for I&I Diseases At 2024 Inaugural R&D Day Include - Marketscreener.com
Apogee Therapeutics price target raised to $110 from $95 at Guggenheim - MSN
Braidwell LP Lowers Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics Announces Agenda for Virtual R&D Day - Marketscreener.com
Apogee Therapeutics Sets R&D Day to Unveil APG808 Clinical Trial Results, Pipeline Updates | APGE Stock News - StockTitan
Vestal Point Capital LP Buys Shares of 136,500 Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Guggenheim lifts Apogee Therapeutics shares target on strategy By Investing.com - Investing.com Australia
Long Term Trading Analysis for (APGE) - Stock Traders Daily
Apogee Therapeutics Inc Azioni (APGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apogee Therapeutics Inc Azioni (APGE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Dec 11 '24 |
Option Exercise |
22.86 |
1,815 |
41,491 |
262,613 |
| Dambkowski Carl | Chief Medical Officer |
Dec 11 '24 |
Sale |
48.76 |
4,540 |
221,363 |
258,073 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):